DOCSLIB.ORG

Hematology Drugs in the Pipeline

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Hematology Drugs in the Pipeline 102 HemOnc today | NOVEMBER 25, 2015 | Healio.com/HemOnc Hematology Drugs in the Pipeline HEMONC TODAY presents the most recent information about hematology drugs in the pipeline. Drugs listed here are in phase 2 or phase 3 development for a variety of indications. Clinicians can use this chart as a quick reference to learn about the status of those drugs that may be clinically significant to their practice. To view the entire chart online, go to www.Healio.com/HematologyPipeline. Generic name (Brand name, Manufacturer) Indication(s) Development status A6 peptide (Angstrom Pharmaceuticals) chronic lymphocytic leukemia, small lymphocytic lymphoma phase 2 AAV5-hFIX (UniQure Biopharma) hemophilia phase 2 ABC294640 (RedHill Biopharma) diffuse large B-cell lymphoma phase 2 abemaciclib (Eli Lilly) mantle cell lymphoma phase 2 abexinostat (Pharmacyclics) follicular lymphoma, mantle cell lymphoma phase 2 ABP 798 (Allergan/Amgen) non-Hodgkin’s lymphoma phase 3 ACP-196 (Acerta Pharma) B-cell malignancies (combination therapy), mantle cell lymphoma phase 2 READ PERSPECTIVE on this drug from Richard R. chronic lymphocytic leukemia phase 3 Furman, MD, on page 108. ACP-319 (Acerta Pharma) B-cell lymphoma (combination therapy), chronic lymphocytic leukemia phase 2 (combination therapy) adeno-associated virus serotype 8 Factor IX gene therapy hemophilia B phase 2 (AskBio009, Baxalta) AEB071 (Novartis) diffuse large B-cell lymphoma (combination therapy for CD79-mutant or phase 2 ABC-subtype disease) AFM 13 (Affimed Therapeutics) Hodgkin’s lymphoma phase 2 alisertib (Millennium) peripheral T-cell lymphoma (relapsed or refractory) phase 3 ALT-803 (Altor BioScience) hematologic malignancies, multiple myeloma phase 2 alvocidib (Tolero Pharmaceuticals) acute myelogenous leukemia (relapsed or refractory) phase 2 acute myelogenous leukemia (first-line) phase 3 andexanet alfa (Portola Pharmaceuticals) Factor Xa inhibitor antidote phase 3 antihemophilic factor [recombinant], porcine sequence (Obizur, Baxalta) hemophilia A, hemophilia B phase 3 AR-42 (Arno Therapeutics) hematologic malignancies phase 2 ASP2215 (Astellas) acute myelogenous leukemia phase 3 AST-VAC1 (Asterias Biotherapeutics) acute myelogenous leukemia phase 2 AT7519 (Astex Pharmaceuticals) multiple myeloma phase 2 azacitidine for injection (Vidaza, Celgene) acute myelogenous leukemia (post-induction maintenance) phase 3 BAX 111 (Baxalta) von Willebrand’s disease phase 3 BAX 335 (Baxalta) Factor IX gene therapy in adults with hemophilia B phase 2 BAX 555 (Baxalta) sickle cell disease phase 2 BAX 855 (Baxalta) hemophilia A phase 3 BB305 (Lentiglobin, Bluebird Bio) beta-thalassemia, sickle cell disease phase 2 BC8-I-131 construct (Iomab-B, Actinium Pharmaceuticals) hematopoietic stem cell transplantation in acute lymphoblastic leukemia phase 2 bendamustine (Treanda, Teva Oncology) mantle cell lymphoma phase 2 betrixaban (Portola Pharmaceuticals) Factor Xa inhibitor phase 3 BI 695500 (Boehringer Ingelheim) follicular lymphoma (first-line) phase 3 BI 836858 (Boehringer Ingelheim) myelodysplastic syndrome phase 2 birinapant (TetraLogic Pharmaceuticals) cutaneous T-cell lymphoma, myelodysplastic syndrome phase 2 Bismab-A (Actinium Pharmaceuticals) acute myelogenous leukemia phase 2 BL-8040 (BioLineRx) acute myelogenous leukemia (combination therapy) phase 2 HemOnc today | NOVEMBER 25, 2015 | Healio.com/HemOnc 103 Hematology Drugs in the Pipeline Generic name (Brand name, Manufacturer) Indication(s) Development status blinatumomab (Blincyto, Amgen) acute lymphoblastic leukemia (relapsed or refractory Philadelphia chromo- phase 2 some-positive disease), diffuse large B-cell lymphoma acute lymphoblastic leukemia (relapsed or refractory disease) phase 3 bortezomib (Velcade, Millennium) diffuse large B-cell lymphoma phase 2 mantle cell lymphoma (first-line) phase 3 bosutinib (Bosulif, Pfizer) chronic myeloid leukemia (first-line) phase 3 BP-100-1-01 (Bio-Path Holdings) acute myelogenous leukemia phase 2 BPX-501 (Bellicum Pharmaceuticals) acute lymphoblastic leukemia, acute myelogenous leukemia, chronic lym- phase 2 phocytic leukemia, chronic myeloid leukemia, non-Hodgkin’s lymphoma brentuximab vedotin (Adcetris, Seattle Genetics) diffuse large B-cell lymphoma (CD30-positive disease), Hodgkin’s lymphoma phase 2 (first-line therapy for elderly patients) cutaneous T-cell lymphoma (relapsed CD30-positive disease), Hodgkin’s lym- phase 3 phoma (first-line), Hodgkin’s lymphoma (post-transplant relapse prevention), T-cell lymphoma (CD30-positive mature disease) BVD-523 (BioMed Valley Discoveries) acute myelogenous leukemia, myelodysplastic syndrome phase 2 calaspargase pegol (Baxalta) acute lymphoblastic leukemia phase 3 carfilzomib (Kyprolis, Onyx Pharmaceuticals) multiple myeloma (first-line therapy) phase 3 carlecortemcel-L (StemEx; Gamida Cell and Teva) hematologic malignancies phase 3 CC-486 (Celgene) myelodysplastic syndrome (post hypomethylating agent failure) phase 2 acute myelogenous leukemia (post-induction maintenance), myelodysplastic phase 3 syndrome (lower-risk disease) CDX-301 (Celldex Therapeutics) B-cell lymphoma, stem cell transplantation in hematologic malignancies phase 2 cerdulatinib (Portola Pharmaceuticals) chronic lymphocytic leukemia, non-Hodgkin’s lymphoma phase 2 CMD-003 (Cell Medica) EBV-positive, extranodal natural killer T-cell lymphoma phase 2 CNDO-109 (Fortress Biotech) acute myelogenous leukemia phase 2 coagulation Factor VIIa recombinant (LR769, rEVO Biologics) hemophilia A, hemophilia B phase 3 coltuximab ravtansine (Immunogen) diffuse large B-cell lymphoma phase 2 copanlisib (Bayer) diffuse large B-cell lymphoma phase 2 non-Hodgkin’s lymphoma phase 3 cord blood stem cell therapy (NiCord, Gamida Cell) hematologic malignancies phase 2 crenolanib (Arog Pharmaceuticals) acute myelogenous leukemia (newly diagnosed disease, maintenance phase 2 therapy after bone marrow transplantation) acute myelogenous leukemia (relapsed or refractory disease) phase 3 CTL019 (Novartis) acute lymphoblastic leukemia phase 2 CX-01 (Cantex Pharmaceuticals) acute myelogenous leukemia phase 2 cytarabine:daunorubicin (CPX-351, Celator Pharmaceuticals) acute myelogenous leukemia, myelodysplastic syndrome (high-risk disease), phase 2 pre-conditioning before hematopoietic stem cell transplantation dabigatran etexilate (Pradaxa, Boehringer Ingelheim) stroke prevention in patients with nonvalvular oral anticoagulation phase 3 damoctocog alfa pegol (Bayer) hemophilia phase 3 daratumumab (Janssen) multiple myeloma (first-line therapy; first-line combination therapy; combi- phase 3 nation therapy for recurrent or relapsed disease) READ PERSPECTIVE on this drug from Paul G. Richardson, MD, on page 108, and Ruben Niesvizky, MD, on page 108. darbepoetin alfa (Aranesp, Amgen) myelodysplastic syndrome (low-risk disease) phase 3 darinaparsin (SP-02, Solasia Pharma) peripheral T-cell lymphoma phase 2 dasatinib (Sprycel, Bristol-Myers Squibb) leukemia (pediatric patients) phase 2 denosumab (Xgeva, Amgen) prevention of skeletal-related events in multiple myeloma phase 3 104 HemOnc today | NOVEMBER 25, 2015 | Healio.com/HemOnc Hematology Drugs in the Pipeline Generic name (Brand name, Manufacturer) Indication(s) Development status DFP-10917 (Delta-Fly Pharma) acute lymphoblastic leukemia, acute myelogenous leukemia phase 2 DI-Leu16-IL2 (Alopexx Oncology) non-Hodgkin’s lymphoma phase 2 DKN-01 (HealthCare Pharmaceuticals) multiple myeloma phase 2 duvelisib (AbbVie and Infinity Pharmaceuticals) non-Hodgkin’s lymphoma (refractory indolent disease) phase 2 chronic lymphocytic leukemia (relapsed or refractory disease), follicular phase 3 lymphoma (previously treated disease) E6201 (Strategia Therapeutics) hematologic malignancies phase 2 elotuzumab (AbbVie and Bristol-Myers Squibb) multiple myeloma (combination therapy, second-line) phase 2 READ PERSPECTIVE on this drug from Ruben multiple myeloma (combination therapy, first-line; combination therapy for phase 3 Niesvizky, MD, on page 108. relapsed or refractory disease) eltrombopag (Promacta, Novartis) myelodysplastic syndrome phase 2 entospletinib (Gilead Sciences) hematologic malignancies phase 2 epratuzumab (Immunomedics) leukemia, lymphoma phase 2 EPZ-6438 (Epizyme) non-Hodgkin’s lymphoma phase 2 ERY-ASP (Erytech Pharma) acute lymphoblastic leukemia (adults) phase 2 everolimus (Afinitor, Novartis) diffuse large B-cell lymphoma phase 3 FF-10501 (Strategia Therapeutics and Fujifilm Pharmaceuticals USA) hematologic malignancies phase 2 filanesib (Array BioPharma) multiple myeloma phase 2 ganetespib (Synta Pharmaceuticals) acute myelogenous leukemia phase 2 GC1101C (Green Cross) hemophilia A phase 3 glasdegib (PF-04449913, Pfizer) acute myelogenous leukemia, myelodysplastic syndrome phase 2 GO-203-2c (Genus Oncology) acute myelogenous leukemia (relapsed or refractory disease) phase 2 GP2013 (Novartis) chronic lymphocytic leukemia, non-Hodgkin’s lymphoma guadecitabine (SGI-110, Astex Pharmaceuticals) hematologic malignancies phase 3 HSC835 (Novartis) hematologic malignancies in single umbilical cord blood transplantation phase 2 HSV-Tk (MolMed) acute leukemia (high-risk disease) phase 3 human-cl rhFVIII (Octapharma) hemophilia A phase 3 ibrutinib (Imbruvica; Pharmacyclics and Janssen) chronic lymphocytic leukemia (single-agent therapy for treatment-naive phase 3 patients; combination therapy for relapsed or refractory disease), diffuse large B-cell lymphoma (combination therapy for newly diagnosed non- germinal center B-cell subtype), mantle cell lymphoma (single-agent
Load more

Recommended publications
  • For Acute Myeloid Leukemia
    Published OnlineFirst September 21, 2010; DOI: 10.1158/1078-0432.CCR-10-0382 Published OnlineFirst on September 21, 2010 as 10.1158/1078-0432.CCR-10-0382 Clinical Therapy Clinical Cancer Research Sequential Cytarabine and α-Particle Immunotherapy with Bismuth-213–Lintuzumab (HuM195) for Acute Myeloid Leukemia Todd L. Rosenblat1, Michael R. McDevitt1, Deborah A. Mulford1, Neeta Pandit-Taskar1, Chaitanya R. Divgi1, Katherine S. Panageas1, Mark L. Heaney1, Suzanne Chanel1, Alfred Morgenstern2, George Sgouros1, Steven M. Larson1, David A. Scheinberg1, and Joseph G. Jurcic1 Abstract Purpose: Lintuzumab (HuM195), a humanized anti-CD33 antibody, targets myeloid leukemia cells and has modest single-agent activity against acute myeloid leukemia (AML). To increase the potency of the antibody without the nonspecific cytotoxicity associated with β-emitters, the α-particle–emitting ra- dionuclide bismuth-213 (213Bi) was conjugated to lintuzumab. This phase I/II trial was conducted to determine the maximum tolerated dose (MTD) and antileukemic effects of 213Bi-lintuzumab, the first targeted α-emitter, after partially cytoreductive chemotherapy. Experimental Design: Thirty-one patients with newly diagnosed (n = 13) or relapsed/refractory (n = 18) AML (median age, 67 years; range, 37-80) were treated with cytarabine (200 mg/m2/d) for 5 days followed by 213Bi-lintuzumab (18.5-46.25 MBq/kg). Results: The MTD of 213Bi-lintuzumab was 37 MB/kg; myelosuppression lasting >35 days was dose limiting. Extramedullary toxicities were primarily limited to grade ≤2 events, including infusion-related reactions. Transient grade 3/4 liver function abnormalities were seen in five patients (16%). Treatment- related deaths occurred in 2 of 21 (10%) patients who received the MTD.
    [Show full text]
  • CD74 Targeted Nanoparticles As Dexamethasone Delivery System for B Lymphoid Malignancies
    CD74 targeted nanoparticles as Dexamethasone Delivery System for B lymphoid malignancies DISSERTATION Presented in Partial Fulfillment of the Requirements for the Degree Doctor of Philosophy in the Graduate School of The Ohio State University By Georgia Triantafillou, MPH Integrated Biomedical Sciences Graduate Program The Ohio State University 2011 Dissertation Committee John C. Byrd, MD, advisor Natarajan Muthusamy, PhD co-advisor Robert J.Lee, PhD, co-advisor Mitch A.Phelps, PhD, co-advisor Guido Marcucci, MD committee member Susheela Tridandapani, PhD committee member Copyright page Georgia Triantafillou 2011 ABSTRACT Chronic Lymphocytic Leukemia (CLL) is the most common adult leukemia and is not curable with standard therapy. In CLL the B lymphocytes appear morphologically mature but immunologically express less mature B cell makers. Specifically, the CLL B cells co-express surface antigens including CD19, CD20, CD5, CD23. Due to nonspecific delivery of the drugs to malignant as well as normal cells, patients experience numerous side effects. Targeted drug delivery to cancer cells is a desirable goal for all anti cancer strategies. Corticosteroids have been proven to be a beneficial and well established part of CLL treatment. Dexamethasone(DEX) is frequently used in CLL therapies as well as other malignancies and antiinflammatory diseases. However, DEX nonspecifically enters all tissues inducing various toxicities to patients. Therefore, DEX treatment is often discontinued or not administered to certain patients. We aimed to deliver this efficient clinical agent via a targeted delivery vehicle and examine its effect on its target B-CLL cells. The main scope of the work presented is the creation of a sterically stable nanoparticle, an ii immunoliposome (ILP), that has DEX encapsulated in its interior and a monoclonal antibody(Mab) in its exterior targeting CLL B cells expressing the surface antigen that is recognized by the Mab.
    [Show full text]
  • Predictive QSAR Tools to Aid in Early Process Development of Monoclonal Antibodies
    Predictive QSAR tools to aid in early process development of monoclonal antibodies John Micael Andreas Karlberg Published work submitted to Newcastle University for the degree of Doctor of Philosophy in the School of Engineering November 2019 Abstract Monoclonal antibodies (mAbs) have become one of the fastest growing markets for diagnostic and therapeutic treatments over the last 30 years with a global sales revenue around $89 billion reported in 2017. A popular framework widely used in pharmaceutical industries for designing manufacturing processes for mAbs is Quality by Design (QbD) due to providing a structured and systematic approach in investigation and screening process parameters that might influence the product quality. However, due to the large number of product quality attributes (CQAs) and process parameters that exist in an mAb process platform, extensive investigation is needed to characterise their impact on the product quality which makes the process development costly and time consuming. There is thus an urgent need for methods and tools that can be used for early risk-based selection of critical product properties and process factors to reduce the number of potential factors that have to be investigated, thereby aiding in speeding up the process development and reduce costs. In this study, a framework for predictive model development based on Quantitative Structure- Activity Relationship (QSAR) modelling was developed to link structural features and properties of mAbs to Hydrophobic Interaction Chromatography (HIC) retention times and expressed mAb yield from HEK cells. Model development was based on a structured approach for incremental model refinement and evaluation that aided in increasing model performance until becoming acceptable in accordance to the OECD guidelines for QSAR models.
    [Show full text]
  • Research in Your Backyard Developing Cures, Creating Jobs
    Research in Your Backyard Developing Cures, Creating Jobs PHARMACEUTICAL CLINICAL TRIALS IN ILLINOIS Dots show locations of clinical trials in the state. Executive Summary This report shows that biopharmaceutical research com- Quite often, biopharmaceutical companies hire local panies continue to be vitally important to the economy research institutions to conduct the tests and in Illinois, and patient health in Illinois, despite the recession. they help to bolster local economies in communities all over the state, including Chicago, Decatur, Joliet, Peoria, At a time when the state still faces significant economic Quincy, Rock Island, Rockford and Springfield. challenges, biopharmaceutical research companies are conducting or have conducted more than 4,300 clinical For patients, the trials offer another potential therapeutic trials of new medicines in collaboration with the state’s option. Clinical tests may provide a new avenue of care for clinical research centers, university medical schools and some chronic disease sufferers who are still searching for hospitals. Of the more than 4,300 clinical trials, 2,334 the medicines that are best for them. More than 470 of the target or have targeted the nation’s six most debilitating trials underway in Illinois are still recruiting patients. chronic diseases—asthma, cancer, diabetes, heart dis- ease, mental illnesses and stroke. Participants in clinical trials can: What are Clinical Trials? • Play an active role in their health care. • Gain access to new research treatments before they In the development of new medicines, clinical trials are are widely available. conducted to prove therapeutic safety and effectiveness and compile the evidence needed for the Food and Drug • Obtain expert medical care at leading health care Administration to approve treatments.
    [Show full text]
  • Advances in Anticancer Antibody-Drug Conjugates and Immunotoxins
    Send Orders for Reprints to [email protected] Recent Patents on Anti-Cancer Drug Discovery, 2014, 9, 35-65 35 Advances in Anticancer Antibody-Drug Conjugates and Immunotoxins Franco Dosio1,*, Barbara Stella1, Sofia Cerioni1, Daniela Gastaldi2 and Silvia Arpicco1 1Dipartimento di Scienza e Tecnologia del Farmaco, University of Torino, Torino, I-10125, Italy; 2Dipartimento di Bio- tecnologie Molecolari e Scienze per la Salute, University of Torino, Torino, I-10125, Italy Received: December 13, 2012; Accepted: February 21, 2013; Revised: March 7, 2013 Abstract: Antibody-delivered drugs and toxins are poised to become important classes of cancer therapeutics. These bio- pharmaceuticals have potential in this field, as they can selectively direct highly potent cytotoxic agents to cancer cells that present tumor-associated surface markers, thereby minimizing systemic toxicity. The activity of some conjugates is of particular interest receiving increasing attention, thanks to very promising clinical trial results in hematologic cancers. Over twenty antibody-drug conjugates and eight immunotoxins in clinical trials as well as some recently approved drugs, support the maturity of this approach. This review focuses on recent advances in the development of these two classes of biopharmaceuticals: conventional toxins and anticancer drugs, together with their mechanisms of action. The processes of conjugation and purification, as reported in the literature and in several patents, are discussed and the most relevant results in clinical trials are listed. Innovative technologies and preliminary results on novel drugs and toxins, as reported in the literature and in recently-published patents (up to February 2013) are lastly examined. Keywords: Antibody drug conjugate, anticancer agents, auristatins immunotoxin, calicheamicins, cross-linkers, duocarmycins, maytansinoids.
    [Show full text]
  • Classification Decisions Taken by the Harmonized System Committee from the 47Th to 60Th Sessions (2011
    CLASSIFICATION DECISIONS TAKEN BY THE HARMONIZED SYSTEM COMMITTEE FROM THE 47TH TO 60TH SESSIONS (2011 - 2018) WORLD CUSTOMS ORGANIZATION Rue du Marché 30 B-1210 Brussels Belgium November 2011 Copyright © 2011 World Customs Organization. All rights reserved. Requests and inquiries concerning translation, reproduction and adaptation rights should be addressed to [email protected]. D/2011/0448/25 The following list contains the classification decisions (other than those subject to a reservation) taken by the Harmonized System Committee ( 47th Session – March 2011) on specific products, together with their related Harmonized System code numbers and, in certain cases, the classification rationale. Advice Parties seeking to import or export merchandise covered by a decision are advised to verify the implementation of the decision by the importing or exporting country, as the case may be. HS codes Classification No Product description Classification considered rationale 1. Preparation, in the form of a powder, consisting of 92 % sugar, 6 % 2106.90 GRIs 1 and 6 black currant powder, anticaking agent, citric acid and black currant flavouring, put up for retail sale in 32-gram sachets, intended to be consumed as a beverage after mixing with hot water. 2. Vanutide cridificar (INN List 100). 3002.20 3. Certain INN products. Chapters 28, 29 (See “INN List 101” at the end of this publication.) and 30 4. Certain INN products. Chapters 13, 29 (See “INN List 102” at the end of this publication.) and 30 5. Certain INN products. Chapters 28, 29, (See “INN List 103” at the end of this publication.) 30, 35 and 39 6. Re-classification of INN products.
    [Show full text]
  • Tanibirumab (CUI C3490677) Add to Cart
    5/17/2018 NCI Metathesaurus Contains Exact Match Begins With Name Code Property Relationship Source ALL Advanced Search NCIm Version: 201706 Version 2.8 (using LexEVS 6.5) Home | NCIt Hierarchy | Sources | Help Suggest changes to this concept Tanibirumab (CUI C3490677) Add to Cart Table of Contents Terms & Properties Synonym Details Relationships By Source Terms & Properties Concept Unique Identifier (CUI): C3490677 NCI Thesaurus Code: C102877 (see NCI Thesaurus info) Semantic Type: Immunologic Factor Semantic Type: Amino Acid, Peptide, or Protein Semantic Type: Pharmacologic Substance NCIt Definition: A fully human monoclonal antibody targeting the vascular endothelial growth factor receptor 2 (VEGFR2), with potential antiangiogenic activity. Upon administration, tanibirumab specifically binds to VEGFR2, thereby preventing the binding of its ligand VEGF. This may result in the inhibition of tumor angiogenesis and a decrease in tumor nutrient supply. VEGFR2 is a pro-angiogenic growth factor receptor tyrosine kinase expressed by endothelial cells, while VEGF is overexpressed in many tumors and is correlated to tumor progression. PDQ Definition: A fully human monoclonal antibody targeting the vascular endothelial growth factor receptor 2 (VEGFR2), with potential antiangiogenic activity. Upon administration, tanibirumab specifically binds to VEGFR2, thereby preventing the binding of its ligand VEGF. This may result in the inhibition of tumor angiogenesis and a decrease in tumor nutrient supply. VEGFR2 is a pro-angiogenic growth factor receptor
    [Show full text]
  • Bendamustine in Patients with Relapsed Chronic Lymphocytic Leukaemia
    research paper Randomized phase 2 study of otlertuzumab and bendamustine versus bendamustine in patients with relapsed chronic lymphocytic leukaemia Tadeusz Robak,1 Andrzej Hellmann,2 Summary Janusz Kloczko,3 Javier Loscertales,4 Otlertuzumab (TRU-016) is a humanized anti-CD37 protein therapeutic Ewa Lech-Maranda,5,6 John M. Pagel,7 Anthony Mato,8 John C. Byrd,9 Farrukh that triggers direct caspase-independent apoptosis of malignant B cells and T. Awan,9 Holger Hebart,10 Jose A. induces antibody-dependent cell-mediated cytotoxicity. Patients with Garcia-Marco,11 Brian T. Hill,12 Michael relapsed chronic lymphocytic leukaemia (CLL) received either otlertuzumab Hallek,13,14 Amy J. Eisenfeld,15 Scott C. (20 mg/kg) weekly by IV infusion for two 28-day cycles then every 14 days Stromatt15 and Ulrich Jaeger14,16 for four 28-day cycles and IV bendamustine (70 mg/m2) on Days 1 and 2 1Department of Haematology, Medical University of each cycle for up to six 28-day cycles or bendamustine alone. Thirty-two of Lodz and Copernicus Memorial Hospital, patients were treated with otlertuzumab and bendamustine and 33 with 2 Lodz, Department of Hematology, Medical bendamustine alone. Overall response rate according to the International 3 University of Gdansk, Gdansk, Department of Workshop on Chronic Lymphocytic Leukaemia criteria was 69% in the Haematology, Medical University of Bialystok, otlertuzumab and bendamustine arm and 39% in the bendamustine alone Bialystok, Poland, 4Haematology, Hospital arm (P = 0Á025). Median progression-free survival (PFS) was 15Á9 months Universitario La Princesa, IIS-IP Madrid, Spain, Á 5 in the otlertuzumab and bendamustine arm and 10 2 months in the ben- Department of Haematology, Institute of Haema- = Á tology and Transfusion Medicine, Warsaw, damustine alone arm (P 0 0192).
    [Show full text]
  • Antibody Drug Conjugates in Lymphoma
    Review: Clinical Trial Outcomes Nathwani & Chen Antibody drug conjugates in lymphoma 6 Review: Clinical Trial Outcomes Antibody drug conjugates in lymphoma Clin. Investig. (Lond.) Antibody drug conjugates (ADCs) are comprised of monoclonal antibodies physically Nitya Nathwani1 & Robert linked to cytotoxic molecules. They expressly target cancer cells by delivering cytotoxic Chen*,1 agents to cells displaying specific antigens, and minimize damage to normal tissue. The 1Department of Hematology & Hematopoietic Cell Transplantation, City efficacy and tolerability of these agents are primarily determined by the target antigen, of Hope, Duarte, CA, USA the cytotoxic agent and the linker connecting the cytotoxic agent to the monoclonal *Author for correspondence: antibody. Following advances in technology, clinical trials have demonstrated greater Tel.: +626 256 4673 (ext. 65298) efficacy for ADCs compared with the corresponding naked monoclonal antibodies. Fax: +626 301 8116 This review summarizes the features of current clinically active ADCs in lymphoma and [email protected] emphasizes recent clinical data elucidating the benefit of antibody-directed delivery of cytotoxic agents to tumor cells. Keywords: antibody drug conjugates • lymphoma • monoclonal antibodies Lymphoma is the most common hematologic concentration and poor performance status malignancy, and is subdivided into two main are adverse prognostic factors. SEER (Sur- types: Hodgkin lymphoma (HL) and non- veillance, Epidemiology and End Results) Hodgkin lymphoma (NHL). In the United data from the National Cancer Institute, States, there are an estimated 731,277 people 2013 has revealed a significant improvement 10.4155/CLI.14.73 living with or in remission from lymphoma. in survival rates in this group of diseases in In 2013, there were an estimated 79,030 new the last four decades.
    [Show full text]
  • Guide to Treatment Role of Antibodies in Acute Leukemia: Focus on Transplant-Eligible Populations
    PRACTICE AID Guide to Treatment Role of Antibodies in Acute Leukemia: Focus on Transplant-Eligible Populations Acute Myeloid Leukemia DRUG STATUS TARGET DOSE EU EMA approved: In combination with daunorubicin and Induction: 3 mg/m2 (up to 5 mg/m2 in EU and 4.5 mg/m2 in US) cytarabine for pts aged ≥15 y with previously untreated, on d 1, 4, and 7 in combination with daunorubicin and cytarabine de novo CD33+ AML, except APL CD33 Consolidation: 3 mg/m2 (up to 5 mg/m2 in EU and 4.5 mg/m2 in US) Gemtuzumab US FDA approved: Newly diagnosed CD33+ AML in adults and 1,2 on d 1 in combination with daunorubicin and cytarabine ozogamicin pediatric pts aged ≥1 month; R/R CD33+ AML in adults and Please consult label for single-agent dosing and dosing in R/R AML. pediatric pts aged 2 y Phase 3 SIERRA study CD45 Adults aged ≥55 y with active R/R AML, adequate organ Dosimetry directed (SIERRA study) Iomab-B3 function, and related/unrelated matched donor (BC8 mAb linked to radioisotope iodine-131) Acute Lymphoblastic Leukemia EU EMA approved: Adults with R/R CD22+ B-cell ALL; adults Cycle 1 dose: 0.8 mg/m2 on d 1; 0.5 mg/m2 on days 8 and 15 for 21 d 2 Inotuzumab with Ph+ R/R B-cell ALL who failed treatment with at least one TKI CD22 Patients in CR/CRi: 0.5 mg/m on days 1, 8, and 15 for 28 d ozogamicin4,5 US FDA approved: Adults with R/R CD22+ B-cell ALL Patients not in CR/CRi: Use cycle 1 dose for 28 d EU Dose: By patient’s weight (≥45 kg = 9 mcg/d on d 1-7 and 28 mcg/d on EU EMA approved: Adults with B-cell ALL who are in d 8-28; <45 kg = 5 mcg/m2/d on
    [Show full text]
  • Whither Radioimmunotherapy: to Be Or Not to Be? Damian J
    Published OnlineFirst April 20, 2017; DOI: 10.1158/0008-5472.CAN-16-2523 Cancer Perspective Research Whither Radioimmunotherapy: To Be or Not To Be? Damian J. Green1,2 and Oliver W. Press1,2,3 Abstract Therapy of cancer with radiolabeled monoclonal antibodies employing multistep "pretargeting" methods, particularly those has produced impressive results in preclinical experiments and in utilizing bispecific antibodies, have greatly enhanced the thera- clinical trials conducted in radiosensitive malignancies, particu- peutic efficacy of radioimmunotherapy and diminished its toxi- larly B-cell lymphomas. Two "first-generation," directly radiola- cities. The dramatically improved therapeutic index of bispecific beled anti-CD20 antibodies, 131iodine-tositumomab and 90yttri- antibody pretargeting appears to be sufficiently compelling to um-ibritumomab tiuxetan, were FDA-approved more than a justify human clinical trials and reinvigorate enthusiasm for decade ago but have been little utilized because of a variety of radioimmunotherapy in the treatment of malignancies, particu- medical, financial, and logistic obstacles. Newer technologies larly lymphomas. Cancer Res; 77(9); 1–6. Ó2017 AACR. "To be, or not to be, that is the question: Whether 'tis nobler in the pembrolizumab (anti-PD-1), which are not directly cytotoxic mind to suffer the slings and arrows of outrageous fortune, or to take for cancer cells but "release the brakes" on the immune system, arms against a sea of troubles, And by opposing end them." Hamlet. allowing cytotoxic T cells to be more effective at recognizing –William Shakespeare. and killing cancer cells. Outstanding results have already been demonstrated with checkpoint inhibiting antibodies even in far Introduction advanced refractory solid tumors including melanoma, lung cancer, Hodgkin lymphoma and are under study for a multi- Impact of monoclonal antibodies on the field of clinical tude of other malignancies (4–6).
    [Show full text]
  • Chemotherapeutic Treatment of Acute Myeloid Leukemia
    Clinical Trial Outcomes Mahdi, Mahdi & Knapper Chemotherapeutic treatment of acute myeloid leukemia 5 Clinical Trial Outcomes Chemotherapeutic treatment of acute myeloid leukemia: incorporating the results of recent clinical trials Clin. Invest. (Lond.) Better outcomes for patients with acute myeloid leukemia over the last 30 years have Ali J Mahdi*,1, Eamon J been largely achieved by improvements in supportive care measures rather than Mahdi1 & Steven Knapper1 therapeutic advances. The combination of daunorubicin and cytarabine has remained 1Cardiff University School of Medicine, Hematology Department, Heath Park, the standard of care for patients undergoing intensive induction–consolidation Cardiff CF14 4XN, UK treatment. In less fit older patients, low-dose cytarabine is the equivalent, although *Author for correspondence: the hypomethylating agent azacitidine may be challenging current practice. [email protected] Enhanced understanding of disease pathogenesis and therapy resistance has enabled the entry of novel chemotherapeutic and nonchemotherapeutic agents into clinical development with varied levels of activity. This article examines the evidence behind established chemotherapy practices for intensive and nonintensive acute myeloid leukemia treatments with an emphasis on emerging clinical trial data from novel chemotherapeutic and nonchemotherapeutic agents. Keywords: acute myeloid leukemia • aminopeptidase inhibitors • farnesyl transferase inhibitors • FLT3 inhibitors • gemtuzumab ozogamicin • histone deacytylase inhibitors • hypomethylating • Polo-like kinase 1 inhibitors Methodology AML cases [7]. Older patients over the age of 10.4155/CLI.14.112 An electronic database search (EMBASE, 60 years thus represent an important popula- MEDLINE and PubMed) was undertaken tion from both demographic and therapeutic to identify and review clinical studies in perspectives. Older patients frequently have acute myeloid leukemia (AML) undertaken multiple comorbidities, unfavorable cyto- between 1 January 2009 and 1 June 2014.
    [Show full text]